Prognostic factors in patients with advanced cholangiocarcinoma: Role of surgery, chemotherapy and body mass index

World Journal of Gastroenterology

Volumn 14, Issue 20, 2008, Pages 3224-3230

  Farhat, Mirna H ^a   Shamseddine, Ali I ^a   Tawil, Ayman N ^a   Berjawi, Ghina ^a   Sidani, Charif ^a   Shamseddeen, Wael ^a   Barada, Kassem A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Biliary tract cancer; Bilirubin; Chemotherapy; Cholangiocarcinoma; Prognosis

Indexed keywords

BILIRUBIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; BILIRUBIN BLOOD LEVEL; BODY MASS; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; LEBANON; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 48949093689     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3224     Document Type: Article

References (56)

1. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517; discussion 517-519
2. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14: 109-114
3. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 189-199
4. Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, Lui WY, Liu TJ, P'eng FK. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223: 384-394
5. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol 2007; 23: 317-323
6. Malhi H, Gores GJ. Review article: the modem diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 2006; 23: 1287-1296
7. Lee GW, Kang JH, Kim HG, Lee JS, Lee JS, Jang JS. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 2006; 29: 127-131
8. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813
9. Farley DR, Weaver AL, Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995; 70: 425-429
10. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902
11. Yoshida T, Matsumoto L Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002; 137: 69-73
12. Kelley ST, Bloomston M, Serafini F, Carey LC, Karl RC, Zervos E, Goldin S, Rosemurgy P, Rosemurgy AS. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004; 70: 743-748; discussion 748-749
13. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695
14. Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, Chen QB, Wu MC. Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2004; 3: 453-457
15. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005; 16 Suppl 2: ii93-ii96
16. Zhang J, Su XQ, Wu XJ, Liu YH, Wang H, Zong XN, Wang Y, Ji JF. Effect of body mass index on adenocarcinoma of gastric cardia. World J Gastroenterol 2003; 9: 2658-2661
17. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 2006; 68: 741-746
18. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ. Relationship of ovarian neoplasms and body mass index. J Reprod Med 2005; 50: 595-602
19. Enger SM, Greif JM, Polikoff J, Press M. Body weight correlates with mortality in early-stage breast cancer. Arch Surg 2004; 139: 954-958; discussion 958-960
20. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638
21. Lee J, Wang H, Chia KS, Koh D, Hughes K. The effect of being overweight on cancer incidence and all-cause mortality in Asians: a prospective study in Singapore. Int J Epidemiol 2002; 31: 875-876
22. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21
23. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91: 421-430
24. Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, Bueno de Mesquita HB, Ghadirian P, Jain M, Przewozniak K, Baghurst P, Moerman CJ, Simard A, Howe GR, McMichael AJ, Hsieh CC, Walker AM. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997; 89: 1132-1138
25. American Joint Commiftee on Cancer Staging Manual. 6th ed. Philadelphia: Springer, 2002: 145-150
26. Sibai AM, Hwalla N, Adra N, Rahal B. Prevalence and covariates of obesity in Lebanon: findings from the first epidemiological study. Obes Res 2003; 11: 1353-1361
27. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253
28. Zhang BH, Cheng QB, Luo XJ, Zhang YJ, Jiang XQ, Zhang BH, Yi B, Yu WL, Wu MC. Surgical therapy for hiliar cholangiocarcinoma: analysis of 198 cases. Hepatobiliary Pancreat Dis Int 2006; 5: 278-282
29. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol 2007; 33: 202-207
30. Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005; 31: 533-539
31. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 2000; 47: 644-649
32. Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002; 183: 679-685
33. Harrison LE, Fong Y, Klimstra DS, Zee SY, Blumgart LH. Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma. Br J Surg 1998; 85: 1068-1070
34. Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002; 49: 311-316
35. Havlik R, Sbisa E, Tullo A, Kelly MD, Mitry RR, Jiao LR, Mansour MR, Honda K, Habib NA. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. Hepatogastroenterology 2000; 47: 927-931
36. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H, Sueda T. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol 2007; 95: 207-212
37. Ramacciato G, Di Benedetto F, Cautero N, Masetti M, Mercantini P, Corigliano N, Nigri G, Lauro A, Ercolani G, Del Gaudio M, De Ruvo N, Pinna AD. [Prognostic factors and long term outcome after surgery for hilar cholangiocarcinoma. Univariate and multivariate analysis] Chir Ital 2004; 56: 749-759
38. Malka D, Boige V, Dromain C, Debaere T, Pocard M, Ducreux M. Biliary tract neoplasms: update 2003. Curr Opin Oncol 2004; 16: 364-371
39. Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2006; 2: 509-514
40. Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, Amano H, Wada K. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998; 45: 2020-2026
41. Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford) 2005; 7: 278-282
42. Price P. Cholangiocarcinoma and the role of radiation and chemotherapy. Hepatogastroenterology 2001; 48: 51-52
43. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linno T, Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600
44. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626
45. Liu XF, Zhou XT, Zou SQ. An analysis of 680 cases of cholangiocarcinoma from 8 hospitals. Hepatobiliary Pancreat Dis Int 2005; 4: 585-588
46. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667
47. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463-473; discussion 473-475
48. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002; 89: 962-970
49. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, Hassan MM. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-1021
50. Welzel TM, Mellemkjaer L, Gloria G, Sakoda LC, Hsing AW, El Ghormli L, Olsen JH, McGlynn KA. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007; 120: 638-641
51. Salti IS, Khogali M, Alain S, Nassar, N, Abu Haidar N, Masri A. The epidemiology of diabetes mellitus in relation to other cardiovascular risk factors in Lebanon. Eastern Mediterranean Health Journal 1997; 3: 462-471
52. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365
53. Khan ZR, Neugut AI, Ahsan H, Chabot JA. Risk factors for biliary tract cancers. Am J Gastroenterol 1999; 94: 149-152
54. Chow WH, McLaughlin JK, Menck HR, Mack TM. Risk factors for extrahepatic bile duct cancers: Los Angeles County, California (USA). Cancer Causes Control 1994; 5: 267-272
55. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006; 17: 901-909
56. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23: 4742-4754